Drugs.com - Clinical Trials

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...

Mar 18, 2025 - 07:11
 0
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 17, 2025-- Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral...
Read More

Tags:

Previous Article

Ulta Beauty Admits Rocky Road Ahead Amid Consumer Uncertainty

Next Article

SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiv...

Related Posts

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

KRRO-110 Receives Orphan Drug Designation from U.S. FDA...

Mar 15, 2025  0

ViiV Healthcare’s Investigational Broadly Neutralising Antibody - N6LS - Successfully Maintains Viral Suppression in Long-Acting Treatment of HIV

ViiV Healthcare’s Investigational Broadly Neutralising ...

Mar 13, 2025  0

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study

Emalex Biosciences’ Lead Candidate Meets Primary and Se...

Mar 1, 2025  0